The 5-year overall survival (OS) in elderly patients with locally advanced head and neck cancers was drastically improved with concurrent chemoradiation versus radiation therapy alone, according to an analysis of the National Cancer Data Base.
Silas Inman
Articles by Silas Inman
The FDA has handed down a breakthrough therapy designation for midostaurin (PKC412) as a potential treatment for adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).
Complimenting best supporting care with panitumumab dropped the risk of death by 30% for patients with RAS wild-type chemorefractory metastatic colorectal cancer (mCRC).
The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.
Marginal improvements were seen in clinical outcomes for patients with metastatic colorectal cancer (CRC) treated with FOLFOXIRI plus bevacizumab compared with FOLFOX plus bevacizumab; however, these findings were inconsistent, according to results from the phase II STEAM trial.
The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) advisory hearing for April 12 to review the new drug application for rociletinib, a treatment for metastatic EGFR T790-mutated non-small cell lung cancer.
The FDA has announced a full clinical hold for trials exploring pacritinib following reports of patient deaths. These deaths stemmed from intracranial hemorrhage, cardiac failure, and cardiac arrest in the phase III PERSIST-2 trial.
Anti–PD-1 agent nivolumab boosted overall survival versus an investigator's choice of therapy in platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) during a recent trial.
"While adverse events across both populations were broadly similar, some did occur more frequently in patients with longer exposure, an observation that is possibly related to the longer duration in this subgroup," said Axel Grothey, MD.
The second interim analysis of the phase III METEOR trial has revealed a statistically significant improvement in overall survival (OS) with cabozantinib (Cometriq) versus everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following progression on one prior therapy, according to a statement from the drug's developer, Exelixis.
Cabozantinib (Cometriq) has receieved a priority review designation from the FDA for patients with advanced renal cell carcinoma (RCC) following progression on one prior therapy, according to Exelixis, the drug's developer.
The FDA has approved eribulin mesylate (Halaven) as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy, based on an improvement in overall survival (OS) in a phase III study.
Pembrolizumab (Keytruda), a PD-1 inhibitor, showcased encouraging activity with some adverse events (AEs) when employed as a treatment for patients with advanced PD-L1
Combining liposomal irinotecan (nal-IRI; MM-398; Onivyde) with 5-fluorouracil (5-FU) plus leucovorin dropped the risk of death in patients with metastatic pancreatic cancer by 25% following progression on a gemcitabine-based regimen, according to updated data from the phase III NAPOLI-1 trial.
Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy boosted overall survival (OS) and generated fewer adverse events (AEs) compared to standard chemoradiation for patients with locally advanced rectal cancer.
The combination of lenvatinib (Lenvima) and everolimus (Afinitor) has been given a priority review status by the FDA as a treatment for patients with metastatic renal cell carcinoma (RCC) following one prior VEGF-targeted therapy.
Novel clinical trials are currently assessing the combination of VEGF-targeted agents and immune checkpoint inhibitors as frontline therapies for patients with metastatic renal cell carcinoma (RCC).
The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine failed to significantly improve the primary endpoint of overall survival (OS) in a phase II study for patients with metastatic urothelial cancer.
Hypofractionated radiotherapy and standard radiation therapy demonstrated similar toxicities and neither prevented PSA increases or disease recurrences for men with intermediate-risk prostate cancer better than the other, according to data from the phase III randomized CHHiP trial reported at the 2016 GU Cancers Symposium.
The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
The FDA has received a new drug application for cabozantinib (Cometriq) as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.
A new method of screening utilizing CA-125 and a risk assessment algorithm could drop risk of mortality from ovarian cancer in certain women, according to findings from the UK Collaborative Trial of Ovarian Cancer Screening.
Afatinib utilized as a frontline treatment reduced risk of progression or death by 27%, as compared to gefitinib in patients with EGFR-mutant non-small cell lung cancer. according to a recent phase IIb trial.
The FDA has assigned a breakthrough therapy status to the third-generation EGFR TKI BI-1482694 as a possible treatment for patients with T790M-positive non
Talimogene laherparepvec (T-VEC; Imlygic) has been approved by the European Comission as a treatment for adult patients with unresectable stage IIIb, IIIc, and IVM1a melanoma that has not spread to the bone, brain, lung, or other viscera, based on the phase III OPTiM study.
The review period for rociletinib for EGFR T790M-positive non-small cell lung cancer (NSCLC) has been extended by the FDA by 3 months. The extension allows ample time to review additional data submitted by the drug's developer, Clovis Oncology.
The PD-L1 inhibitor avelumab showcased promising overall response rates in patients with PD-L1-positive metastatic breast cancer, especially in patients with triple-negative breast cancer.
Neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer, according to a 3-year exploratory analysis of the ExteNET trial.
The SWOG S0777 trial data shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.
A triplet of elotuzumab, lenalidomide, and dexamethasone produced sustained improvements in both progression-free survival and overall survival in patients with relapsed/refractory multiple myeloma, according to a 3-year analysis of the phase III ELOQUENT-2 trial.